EyePoint Pharmaceuticals Inc’s filing revealed that its Director Zaderej Karen L. acquired Company’s shares for reported $29950.0 on May 19 ’25. In the deal valued at $5.99 per share,5,000 shares were bought. As a result of this transaction, Zaderej Karen L. now holds 36,500 shares worth roughly $0.33 million.
Then, Zaderej Karen L. bought 5,000 shares, generating $29,050 in total proceeds. Upon buying the shares at $5.81, the Director now owns 31,500 shares.
Before that, Zaderej Karen L. bought 5,000 shares. EyePoint Pharmaceuticals Inc shares valued at $27,350 were divested by the Director at a price of $5.47 per share. As a result of the transaction, Zaderej Karen L. now holds 26,500 shares, worth roughly $0.24 million.
Citigroup initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to a Buy in a research note published on January 07, 2025; the price target was $33. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Jefferies began covering EYPT with “Buy” recommendation on August 28, 2024. JP Morgan started covering the stock on January 22, 2024. It rated EYPT as “an Overweight”.
Price Performance Review of EYPT
On Friday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock jump 8.36% to $8.94. Over the last five days, the stock has gained 23.48%. EyePoint Pharmaceuticals Inc shares have risen nearly 20.00% since the year began. Nevertheless, the stocks have fallen -3.04% over the past one year. While a 52-week high of $13.98 was reached on 01/07/25, a 52-week low of $3.91 was recorded on 04/09/25. SMA at 50 days reached $6.16, while 200 days put it at $7.77.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 8.44, which if violated will result in even more drops to 7.95. On the upside, there is a resistance level at 9.26. A further resistance level may holdings at 9.59. The Relative Strength Index (RSI) on the 14-day chart is 77.44, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.47, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 4.13%. Stochastics %K at 95.66% indicates the stock is a selling.
The most recent change occurred on November 02, 2023 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
